Overview

A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Status:
Completed
Trial end date:
2020-12-08
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adult subjects.
Phase:
Phase 2
Details
Lead Sponsor:
KalVista Pharmaceuticals, Ltd.